AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$1.21B |
| 2 |
Advanced Micro Devices
AMD
|
+$1.15B |
| 3 |
Quanta Services
PWR
|
+$691M |
| 4 |
Trane Technologies
TT
|
+$684M |
| 5 |
RTX Corp
RTX
|
+$655M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.74B |
| 2 |
Microsoft
MSFT
|
+$2.35B |
| 3 |
Broadcom
AVGO
|
+$744M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$636M |
| 5 |
TSMC
TSM
|
+$590M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.92% |
| 2 | Miscellaneous | 10.92% |
| 3 | Healthcare | 10.85% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Financials | 9.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3276
Nexxen International
NEXN
$506M
| $72.4K | ﹤0.01% |
+11,100
| New | +$87.6K |
2026 Q2
0 quarters
|
|
3277
Epsilon Energy
EPSN
$193M
| $71.5K | ﹤0.01% |
+11,600
| New | +$68.8K |
2026 Q2
0 quarters
|
|
3278
Caribou Biosciences
CRBU
$57.1M
| $70.5K | ﹤0.01% |
+37,080
| New | +$73.3K |
2026 Q2
0 quarters
|
|
3279
Black Diamond Therapeutics
BDTX
$108M
| $68.9K | ﹤0.01% |
+32,340
| New | +$79.1K |
2026 Q2
0 quarters
|
|
3280
Century Therapeutics
IPSC
$264M
| $67.3K | ﹤0.01% |
+29,790
| New | +$68.1K |
2026 Q2
0 quarters
|
|
3281
NLI Holdings
NL
$329M
| $66.8K | ﹤0.01% |
11,455
+1,210
| +12% | +$7.43K |
2025 Q2
4 quarters
|
|
3282
Hello Group
MOMO
$646M
| $65.7K | ﹤0.01% |
11,411
| – | – |
2023 Q1
13 quarters
|
|
3283
Citizens
CIA
$182M
| $64.4K | ﹤0.01% |
12,800
+2,000
| +19% | +$10.9K |
2025 Q3
3 quarters
|
|
3284
Aemetis
AMTX
$93.8M
| $63.2K | ﹤0.01% |
+19,800
| New | +$48.4K |
2026 Q2
0 quarters
|
|
3285
X4 Pharmaceuticals
XFOR
$321M
| $60.2K | ﹤0.01% |
+14,580
| New | +$59.8K |
2026 Q2
0 quarters
|
|
3286
Fossil Group
FOSL
$390M
| $57.8K | ﹤0.01% |
+13,400
| New | +$60.1K |
2026 Q2
0 quarters
|
|
3287
Lucid Diagnostics
LUCD
$78.5M
| $54.3K | ﹤0.01% |
47,200
+25,000
| +113% | +$26.9K |
2025 Q2
4 quarters
|
|
3288
Lineage Cell Therapeutics
LCTX
$253M
| $53.8K | ﹤0.01% |
+34,020
| New | +$47K |
2026 Q2
0 quarters
|
|
3289
ALX Oncology
ALXO
$162M
| $52.8K | ﹤0.01% |
+26,340
| New | +$47.1K |
2026 Q2
0 quarters
|
|
3290
Protalix BioTherapeutics
PLX
$205M
| $52.4K | ﹤0.01% |
24,160
+12,440
| +106% | +$26.3K |
2025 Q2
4 quarters
|
|
3291
Kaltura
KLTR
$220M
| $52K | ﹤0.01% |
42,590
| – | – |
2024 Q2
8 quarters
|
|
3292
Motorsport Games
MSGM
$22.5M
| $50.1K | ﹤0.01% |
12,216
| – | – |
2022 Q3
15 quarters
|
|
3293
CuriosityStream
CURI
$169M
| $48.5K | ﹤0.01% |
+16,400
| New | +$48.5K |
2026 Q2
0 quarters
|
|
3294
TMC The Metals Company
TMC
$1.07B
| $48.1K | ﹤0.01% |
10,300
| – | – |
2025 Q3
3 quarters
|
|
3295
SmartRent
SMRT
$238M
| $48K | ﹤0.01% |
+32,000
| New | +$40.6K |
2026 Q2
0 quarters
|
|
3296
ProKidney
PROK
$295M
| $47.9K | ﹤0.01% |
+26,760
| New | +$49K |
2026 Q2
0 quarters
|
|
3297
Douglas Elliman
DOUG
$145M
| $46.7K | ﹤0.01% |
28,500
+4,100
| +17% | +$7.35K |
2025 Q3
3 quarters
|
|
3298
MacroGenics
MGNX
$143M
| $45.6K | ﹤0.01% |
+15,780
| New | +$59.7K |
2026 Q2
0 quarters
|
|
3299
Goldgroup Mining
GORO
$558M
| $44.4K | ﹤0.01% |
+9,250
| New | +$50.5K |
2026 Q2
0 quarters
|
|
3300
Lifecore Biomedical
LFCR
$243M
| $43.1K | ﹤0.01% |
+11,580
| New | +$58.3K |
2026 Q2
0 quarters
|
|
Similar funds
AllianceBernstein's Q2 2026 Portfolio in Review
As of Q2 2026, AllianceBernstein held 3,456 positions worth $302B, down 2.1% from $309B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
AllianceBernstein withdrew a net $10.1B in Q2 2026, closing 139 positions and reducing 1,179 holdings. Its most notable exit was Hologic, an estimated $75.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 29% a quarter earlier, followed by Miscellaneous and Healthcare.
Against the trend, AllianceBernstein opened a new position in Honeywell Aerospace worth $183M.
- AllianceBernstein's largest Q2 2026 buy was Honeywell Aerospace: 827,059 shares worth $183M.
- AllianceBernstein added most to Micron Technology in Q2 2026, an estimated $1.21B increase.
- AllianceBernstein's biggest Q2 2026 reduction was Amazon, cutting an estimated $3.74B.
- AllianceBernstein fully exited Hologic in Q2 2026, selling an estimated $75.9M.
- AllianceBernstein's ten largest holdings make up 31% of its $302B portfolio in Q2 2026.
- AllianceBernstein opened 228 new positions and closed 139 in Q2 2026.
- AllianceBernstein's portfolio value fell 2.1% quarter-over-quarter to $302B.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.